Colorectal Neoplasms — Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.
Citation(s)
Rationale and Design of a Prospective, Multicenter Phase Ⅱ Clinical Trial of Safety and Efficacy Evaluation of Long Course Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.